Glycine transporter-1 inhibitors: a patent review (2011–2016)

References

• Johnson JW , Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529–531.
   PubMed Web of Science ®Google Scholar
• Wolosker H. NMDA receptor regulation by D-serine: new findings and perspectives. Mol Neurobiol. 2007;36:152–164.
   PubMed Web of Science ®Google Scholar
• Aprison MH. The discovery of the neurotransmitter role of glycine. In: Ottersen OP , Storm Mathisen J , editors. Glycine neurotransmission. Chichester, UK: John Wiley and Sons; 1990. p. 1–23.
   Google Scholar
• Betz H . Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron. 1990;5:383–392.
   PubMed Web of Science ®Google Scholar
• Bliss TV , Collingridge GL . Memories of NMDA receptors and LTP. Trends Neurosci. 1995;18:54–56.
   PubMed Web of Science ®Google Scholar
• Traynelis SF , Wollmuth LP , McBain CJ , et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405–496.
   PubMed Web of Science ®Google Scholar
• Lewis DA , Moghaddam B . Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372–1376.
   PubMed Web of Science ®Google Scholar
• Houman H , Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27:11496–11500.
   PubMed Web of Science ®Google Scholar
• Lewis DA , Curley AA , Glausier JR , et al. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57–67.
   PubMed Web of Science ®Google Scholar
• Dang Y-H , Ma X-C , Zhang J-C , et al. Targeting NMDA receptors in the treatment of major depression. Curr Pharm Des. 2014;20:5151–5159.
   PubMed Web of Science ®Google Scholar
• Szewczyk B , Palucha-Poniewiera A , Poleszak E , et al. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs. 2012;21:91–102.
   PubMed Web of Science ®Google Scholar
• Nishikawa H , Inoue T , Izumi T , et al. SSR504734, a glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats. Behav Pharmacol. 2010;21:576–579.
   PubMed Web of Science ®Google Scholar
• Komatsu H , Furuya Y , Sawada K , et al. Involvement of the strychnine-sensitive glycine receptor in the anxiolytic effects of GlyT-1 inhibitors on maternal separation-induced ultrasonic vocalization in rat pups. Eur J Pharmacol. 2015;746:252–257.
   PubMed Web of Science ®Google Scholar
• Chamberlain SR , Menzies L , Hampshire A . Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science. 2008;321:421–422.
   PubMed Web of Science ®Google Scholar
• Zhou H-Z , Chen S-R , Pan H-L . Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4:379–388.
   PubMedGoogle Scholar
• Lee EJ , Choi SY , Kim E . NMDA receptor dysfunction in autism spectrum disorder. Curr Opin Pharmacol. 2015;20:8–13.
   PubMed Web of Science ®Google Scholar
• Ghasemi M , Schachter SC . The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav. 2011;22:617–640.
   PubMed Web of Science ®Google Scholar
• Chen M , Lu TJ , Chen XJ , et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke. 2008;39:3042–3048.
   PubMed Web of Science ®Google Scholar
• Chao N , Li ST . Synaptic and extrasynaptic glutamate signaling in ischemic stroke. Curr Med Chem. 2014;21:2043–2064.
   PubMed Web of Science ®Google Scholar
• Choo AM , Gedded-Klein DM , Hockenberry A , et al. NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult. Neurochem Int. 2012;60:506–516.
   PubMed Web of Science ®Google Scholar
• (a) Webb TI, Lynch JW. Molecular pharmacology of the glycine receptor chloride channel. Curr Pharm Des. 2007; 13: 2350-2367; (b) Dutertre S, Becker CM, Betz H. Inhibitory glycine receptors: an update. J Biol Chem 2012; 48: 40216-40223; (c) Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004; 84: 1051-1095; (d) Betz H . Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron. 1990;5:383–392.
   PubMed Web of Science ®Google Scholar
• Betz H , Harvey RJ , Schloss P . Structures, diversity and pharmacology of glycine receptors and transporters. In: Möhler H , editor. Pharmacology of GABA and glycine neurotransmission. New York: Springer; 2000. p. 375–401.
   Google Scholar
• (a) Arkai T, Yamano M, Murakami T, Wanaka A, Betz H, Tohyama M. Localization of glycine receptors in the rat central nervous system: an immunocytochemical analysis using monoclonal antibody. Neuroscience. 1988; 25: 613-624; (b) Takahashi T, Momiyama A, Hirai K, Hishinuma F, Akagi H . Functional correlation of fetal and adult forms of glycine receptors with developmental changes in inhibitory synaptic receptor channels. Neuron. 1992;9:1155–1161.
   PubMed Web of Science ®Google Scholar
• Probst A , Cortes R , Palacios JM . The distribution of glycine receptors in the human brain. A light microscopic autoradiographic study using [3h]strychnine. Neuroscience. 1986;17:11–35.
   PubMed Web of Science ®Google Scholar
• Zarbin MA , Wamsley JK , Kuhar MJ . Glycine receptor: light microscopic autoradiographic localization with [3h]strychnine. J Neurosci. 1981;1:532–547.
   PubMed Web of Science ®Google Scholar
• (a) Pourcho RG. Neurotransmitters in the retina. Curr Eye Res. 1996; 15: 797-803; (b) Grunert U . Distribution of GABA and glycine receptors on bipolar and ganglion cells in the mammalian retina. Microsc Res Tech. 2000;50:130–140.
   PubMed Web of Science ®Google Scholar
• Molander A , Soderpalm B . Accumbal strychninie-sensitive glycine receptors: an access point for ethanol to the brain reward system. Alcohol Clin Ex Res. 2005;29:27–37.
   PubMed Web of Science ®Google Scholar
• Molander A , Lof E , Stomberg R , et al. Involvement of accumbal glycine receptors in the regulation of voluntary ethanol intake in the rat. Alcohol Clin Ex Res. 2005;29:38–45.
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU , Wildner H , Yévenes GE . Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev. 2012;92:193–235.
   PubMed Web of Science ®Google Scholar
• (a) Takazawa T, MacDermott AB. Synaptic pathways and inhibitory gates in the spinal cord dorsal horn. Ann NY Acad Sci. 2010; 1198: 153-158; (b) Todd AJ. Plasticity of inhibition in the spinal cord. In pain control, handbook of experimental pharmacology, 2nd ed.; Schaible HG. Ed.; Springer: Berlin Heidelberg, 2015; pp 171-190; (c) Zeilhofer HU, Benke D, Yévenes GE. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Ann Rev Pharmacol Toxicol. 2012; 52: 111-133; (d) Taylor BK. Spinal inhibitory neurotransmission in neuropathic pain. Curr Pain Headache Rep. 2009; 13: 208-214; (e) Zeilhofer HU. Spinal neuroplasticity in chronic pain. E-Neuroforum. 2011; 2: 35-41; (f) Zeilhofer HU. The glycinergic control of spinal pain processing. Cell Mol Life Sci. 2005; 62: 2027-2035; (g) Imlach WL . New approaches to target glycinergic neurotransmission for the treatment of chronic pain. Pharmacol Rep. 2017;116:93–99.
   Google Scholar
• Zafra F , Aragón C , Olivares L , et al. Glycine transporters are differentially expressed among CNS cells. J Neurosci. 1995;15:3952–3969.
   PubMed Web of Science ®Google Scholar
• Zafra F , Gomeza C , Olivares L , et al. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci. 1995;7:1342–1352.
   PubMed Web of Science ®Google Scholar
• Guastella J , Brecha N , Weigmann C , et al. Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci USA. 1992;89:7189–7193.
   PubMed Web of Science ®Google Scholar
• Liu QR , Nelson H , Mandiyan S , et al. Cloning and expression of a glycine transporter from mouse brain. FEBS Lett. 1992;305:110–114.
   PubMed Web of Science ®Google Scholar
• Zafra F , Aragon C , Oliveras L , et al. Glycine transporters are differently expressed among CNS cells. J Neurosci. 1995;15:3952–3969.
   PubMed Web of Science ®Google Scholar
• Gether U , Andersen PH , Larsson OM , et al. Neurotransmitter transporters: molecular function of important drug targets. Trend Pharm Sci. 2006;27:375–383.
   PubMed Web of Science ®Google Scholar
• Olivares L , Argon C , Gimenez C , et al. Analysis of the transmembrane topology of the glycine transporter GLYT1. J Biol Chem. 1997;272:1211–1217.
   PubMed Web of Science ®Google Scholar
• Ponce J , Biton B , Benavides J , et al. Transmembrane domain III plays an important role in ion binding an permeation in the glycine transporter GLYT2. J Biol Chem. 2000;275:13856–13862.
   PubMed Web of Science ®Google Scholar
• Nunez E , Martinez-Maza R , Geerling A , et al. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N-[3-(4ʹ-fluorophenyl)-3-(4ʹ-phenylphenoxy)-propyl]sarcosine. Neuropharmacology. 2005;49:922–934.
   PubMed Web of Science ®Google Scholar
• Olivares L , Argon C , Gimenez C , et al. Carboxyl terminus of the glycine transporter GLYT1 is necessary for correct processing of the protein. J Biol Chem. 1994;269:28400–28404.
   PubMed Web of Science ®Google Scholar
• Adams RH , Sato K , Shimada S , et al. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J Neurosci. 1995;15:2524–2532.
   PubMed Web of Science ®Google Scholar
• Borowsky B, Mezey E, Hoffman BJ. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron. 1993; 10: 851-863.Kim KM, Kingsmore SF, Han H, Yang-Feng TL, Godinot N, Seldin MF, Caron MG, Giros B . Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol Pharmacol. 1994;45:608–617.
   PubMed Web of Science ®Google Scholar
• Borowsky B , Hoffman BJ . Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure. J Biol Chem. 1998;273:29077–29085.
   PubMed Web of Science ®Google Scholar
• Hanley JG , Jones EM , Moss SJ . GABA receptor subunit interacts with a novel splice variant of the glycine transporter, GLYT-1. J Biol Chem. 2000;275:840–846.
   PubMed Web of Science ®Google Scholar
• Ebihara S , Yamamoto T , Obata K , et al. Gene structure and alternative splicing of the mouse glycine transporter type-2. J Biochem Biophys Res Commun. 2004;317:857–864.
   PubMed Web of Science ®Google Scholar
• Lopez-Corcuera B , Aragon C . Solubilization and reconstitution of the sodium-and-chloride-coupled glycine transporter from the rat spinal cord. Eur J Biochem. 1989;181:519–524.
   PubMedGoogle Scholar
• Lopez-Corcuera B , Vazquez J , Aragon C . Purification of the sodium-and-chloride coupled glycine transporter from central nervous system. J Biol Chem. 1991;266:24809–24814.
   PubMed Web of Science ®Google Scholar
• Yamashita A , Singh SK , Kawate T , et al. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature. 2005;437:215–223.
   PubMed Web of Science ®Google Scholar
• Thomas JR , Gedeon PC , Grant BJ , et al. LeuT conformational sampling utilizing accelerated molecular dynamics and principal component analysis. Biophys J. 2012;103:L01–L03.
   PubMed Web of Science ®Google Scholar
• Mallorga PJ , Williams JB , Jacobson M , et al. Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4ʹ-fluorophenyl)-3-(4ʹ-phenylphenoxy)propyl])sarcosine. Neuropharmacology. 2003;45:585–593.
   PubMed Web of Science ®Google Scholar
• Zeng Z , O’Brien JA , Lemaire W , et al. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic an in vivo brain occupancy studies. Nuc Med Biol. 2008;35:315–325.
   PubMed Web of Science ®Google Scholar
• Herdron HJ , Roberts JC , Coulton S , et al. Pharmacological characterization of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology. 2010;59:558–565.
   PubMed Web of Science ®Google Scholar
• Fuchigami T , Haratake M , Magata Y , et al. Synthess and characterization of [125I]2-iodo N-[(S)-{(S)-1-methylpieridin-2-yl}(phenyl)methyl]3-trifluoromethyl-benzamide as a novel imaging probe for glycine transporter 1. Bioorg Med Chem. 2011;19:6245–6253.
   PubMed Web of Science ®Google Scholar
• Hamill TG , Eng W , Jennings A , et al. The synthesis and preclinical evaluation in rhesus monkey of [18F]MK-6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse. 2011;65:261–270.
   PubMed Web of Science ®Google Scholar
• Joshi AD , Sanabria-Bohorquez SM , Bormans G , et al. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015;69:33–40.
   PubMed Web of Science ®Google Scholar
• Passchier J , Gentile G , Porter R , et al. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse. 2010;64:542–549.
   PubMed Web of Science ®Google Scholar
• Gunn RN , Murthy V , Catafau AM , et al. Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1. Synapse. 2011;65:1319–1332.
   PubMed Web of Science ®Google Scholar
• Borroni E , Zhou Y , Ostrowitzki S , et al. Pre-clinical characterization of [11C]RO5013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. NeuroImage. 2013;75:291–300.
   PubMed Web of Science ®Google Scholar
• Wong DF , Ostrowitzki S , Zhou Y , et al. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage. 2013;75:282–290.
   PubMed Web of Science ®Google Scholar
• Jursky F , Nelson N . Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain. J Neurochem. 1996;67:336–344.
   PubMed Web of Science ®Google Scholar
• Cubelos B , Gimenez C , Zafra F . Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex. 2005;15:448–459.
   PubMed Web of Science ®Google Scholar
• Gomeza J , Hülsmann S , Ohno K , et al. Inactivation of the glycine transporter 1 gene discloses a vital role of glial glycine uptake in glycinergic inhibition. Neuron. 2003;40:785–796.
   PubMed Web of Science ®Google Scholar
• Raiteri L , Raiteri M . Functional ‘glial’ GLYT1 glycine transporters expressed in neurons. J Neurochem. 2010;114:647–653.
   PubMed Web of Science ®Google Scholar
• Pow DV , Hendrickson A . Distribution of the glycine transporter in mammalian and non-mammalian retinae. Vis Neurosci. 1999;16:231–239.
   PubMed Web of Science ®Google Scholar
• Lee S , Zhong Y , Yang X . Expression of glycine receptor and transporter on bullfrog retinal Muller cells. Neurosci Lett. 2005;387:75–79.
   PubMed Web of Science ®Google Scholar
• Schlösser L , Barthel F , Brandenburger T , et al. Glycine transporter GlyT1, but not GlyT2, is expressed in rat dorsal root ganglion - possible implications for neuropathic pain. Neurosci Lett. 2015;600:213–219.
   PubMed Web of Science ®Google Scholar
• Howard A , Tahir I , Javed S , et al. Glycine transporter GLYT1 is essential for glycine-mediated protection of human intestinal epithelial cells against oxidative damage. J Physiol. 2010;588:995–1009.
   PubMed Web of Science ®Google Scholar
• Winter M , Funk J , Korner A , et al. Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats. Exp Hematol. 2016;44:964–974.
   PubMed Web of Science ®Google Scholar
• Javitt DC , Zylberman I , Zukin SR , et al. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151:1234–1236.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U , Javitt DC , Ermilov M , et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29–36.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U , Ermilov M , Lichtenberg P , et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55:165–171.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U , Javitt DC , Ermilov M , et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996;169:610–617.
   PubMed Web of Science ®Google Scholar
• Hedron HJ , Godfrey FM , Brown AM . Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmocology. 2001;41:88–96.
   PubMed Web of Science ®Google Scholar
• Lane H , Lin C , Huang Y , et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13:451–460.
   PubMed Web of Science ®Google Scholar
• Lane H , Chang Y , Liu Y , et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62:1196–2004.
   PubMed Web of Science ®Google Scholar
• Lane H , Huang C , Chang Y , et al. Sarcosine (N-methylclycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63:9–12.
   PubMed Web of Science ®Google Scholar
• Porter RA , Dawson LA . GlyT-1 inhibitors: from hits to clinical candidates. Top Med Chem. 2015;13:51–100.
   Google Scholar
• Harvey RJ , Yee BK . Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discovery. 2013;12:866–885.
   PubMed Web of Science ®Google Scholar
• Harsing LG . An overview on GlyT-1 inhibitors under evaluation for the treatment of schizophrenia. Drugs Future. 2013;38:545–558.
   Web of Science ®Google Scholar
• Chue P . Glycine reuptake inhibition as a new therapeutic approach in schizophrenia. Curr Pharm Des. 2013;19:1311–1320.
   PubMed Web of Science ®Google Scholar
• Cioffi CL , Guzzo PR . Inhibitors of glycine transporter-1: potential therapeutics for the treatment of CNS disorders. Curr Top Med Chem. 2016;16:3404–3437.
   PubMed Web of Science ®Google Scholar
• Aubrey KR , Vandenberg RJ . N[3-(4ʹfluorophenyl)-3-(4ʹ-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol. 2001;134:1429–1436.
   PubMed Web of Science ®Google Scholar
• Atkinson BN , Bell SC , De Vivo M , et al. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001;60:1414–1420.
   PubMed Web of Science ®Google Scholar
• Perry KW , Falcone JF , Fell MJ , et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. Cortical Brain Areas. Neuropharmacology. 2008;55:743–754.
   Google Scholar
• Treanor J , Chen H , Murphy O , et al. AMG 747, a novel glycine transporter type-1 (GlyT-1) inhibitor with cognition-enhancing and antipsychotic-like effects in preclinical rodent models of schizophrenia. Poster 152.08/W9, Proceedings of Society for Neuroscience Meeting; 2013 Nov 9–13; San Diego.
   Google Scholar
• Amgen . Glycine transporter-1 inhibitors. WO 2008/002583. 2008.
   Google Scholar
• Ge J , Hamilton M , Shahid D , et al. The effects of Org 25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br J Pharmacol. 2001;133:135.
   Web of Science ®Google Scholar
• (a) Walker GB, Ge J, Cruise L, Hamilton W, Bruin J, Henry B, Hill DR. Characterization of Org 25935: a selective Glyt-1 glycine uptake inhibitor. Schizophr Bull. 2007; 33: 325; (b) Andrews N Ge J, Walker G, Schipper J, Martson HM . Effect of the selective glycine re-uptake (GlyT-1) inhibitor Org 25935 on glycine levels in CSF and dialysates. Eur Neuropsychopharmacology. 2007;17:S497–S498.
   Web of Science ®Google Scholar
• Eddins D , Hamill TG , Puri V , et al. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology. 2014;231:511–519.
   PubMed Web of Science ®Google Scholar
• Castner SA , Murthy NV , Ridler K , et al. Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology. 2014;39:2742–2749.
   PubMed Web of Science ®Google Scholar
• D’Souza DC , Singh N , Elander J , et al. Glycine transporter inhibitor attenuates the psychomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology. 2012;37:1036–1046.
   PubMed Web of Science ®Google Scholar
• Schoemaker JH , Jansen WT , Schipper J , et al. The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014;34:190–198.
   PubMed Web of Science ®Google Scholar
• De Bejczy A , Nations KR , Szegedi A , et al. Efficacy and safety of the glycine transporter-1 inhibitor Org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Ex Res. 2014;38:2427–2435.
   PubMed Web of Science ®Google Scholar
• Lido HH , Jonsson S , Hyytia P , et al. Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects. J Neural Transm. 2017;124:607–619.
   PubMed Web of Science ®Google Scholar
• Depoortère R , Dargazanli G , Estenne-Bouhtou G , et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsycopharmacology. 2005;30:1963–1985.
   PubMed Web of Science ®Google Scholar
• Singer P , Zhang W , Yee BK . SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine. Psychopharmacol. 2013;230:309–317.
   Web of Science ®Google Scholar
• Black MD , Varty GB , Arad M , et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology. 2009;202:385–396.
   PubMed Web of Science ®Google Scholar
• Mezler M , Hornberger W , Mueller R , et al. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol. 2008;74:1705–1715.
   PubMed Web of Science ®Google Scholar
• Bouley D , Pichat P , Dargazanli G , et al. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav. 2008;91:47–58.
   PubMed Web of Science ®Google Scholar
• Glaxo Smith Kline . Glycine transporter inhibitors. WO 2006/067423. 2006.
   Google Scholar
• Glaxo Smith Kline . Compounds. WO 2006/067414. 2006.
   Google Scholar
• Ouellet D , Sutherland S , Wang T , et al. First-time-in-human study with GSK10118921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. Clin Pharmacol Ther. 2011;90:597–604.
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co . Glycine transporter inhibitors. WO 2014/199960. 2014.
   Google Scholar
• F Hoffman Laroche AG. WO 2011/161008. 2011.
   Google Scholar
• F Hoffman Laroche AG . Amido-tropane derivatives. WO 2011/161006. 2011.
   Google Scholar
• F Hoffman Laroche AG . Tetrahydro-pyran derivatives against neurological illnesses. WO 2011/095434. 2011.
   Google Scholar
• F Hoffman Laroche AG . Carbocyclic GLYT1 receptor antagonists. WO 2011/023367. 2011.
   Google Scholar
• Blackaby WP , Lewis RT , Thomson JL , et al. Identification of an orally bioavailable, potent, and selective inhibitor of GlyT1. ACS Med Chem Lett. 2010;1:30–354.
   PubMed Web of Science ®Google Scholar
• Cioffi CL , Wolf MA , Guzzo PR , et al. Design, synthesis, and SAR of N-((1-4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1. Bioorg Med Chem Lett. 2013;23:1257–1261.
   PubMed Web of Science ®Google Scholar
• Cioffi C , Liu S , Wolf M , et al. Synthesis and biological evaluation of N-((1-(4-(sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1. J Med Chem. 2016;59:8473–8494.
   PubMed Web of Science ®Google Scholar
• Albany Molecular Research, Inc . N-[(Sulfonylpiperazinyl)cycloalkyl]methyl carboxamide derivatives as glycine transporter-1 inhibitors and their preparation. WO 2011/153359. 2011.
   Google Scholar
• Abbot GMBH & Co KG . Phenylalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy. WO 2012/020130. 2012.
   Google Scholar
• Abbot GMBH & Co KG . Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy. US 2012/0295881. 2012.
   Google Scholar
• Abbot GMBH & Co KG . Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. WO 2015/055770. 2015.
   Google Scholar
• Abbot GMBH & Co KG . Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy. WO 2012/152915. 2012.
   Google Scholar
• Abbot GMBH & Co KG . Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1. WO 2010/092181. 2010.
   Google Scholar
• Abbot GMBH & Co KG . Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. WO 2013/120835. 2013.
   Google Scholar
• Abbvie, Inc . Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US 2014/0275087. 2014.
   Google Scholar
• Abbvie, Inc . 4,5-Dihydropyrrazole derivatives, pharmaceutical compositions containing them, and their use in therapy. WO 2016/038160. 2016.
   Google Scholar
• Lowe JA , Hou X , Schmidt C , et al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett. 2009;19:2974–2976.
   PubMedGoogle Scholar
• National Center for Advancing Translational Sciences . https://ncats.nih.gov/files/PF-03463275.pdf. (Accessed December 3, 2017). Available from: https://ncats.nih.gov/files/PF-03463275.pdf
   Google Scholar
• Liu C-L , Pettersen B , Seitis G , et al. GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats. Cutan Ocul Toxicol. 2014;33:206–211.
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co . Glycine transporter inhibitors. WO 2011/007899. 20. 2011.
   Google Scholar
• Taisho Pharmaceutical Co . Glycine transporter inhibitor. WO 2010/107115. 2010.
   Google Scholar
• Pinard E , Alanine A , Alberti D , et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methylsulfonyl-2-((S)-2,2,2-trifluoromethylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010;53:460–4614.
   PubMedGoogle Scholar
• Alberti D , Moreau J-L , Lengyel J , et al. Glycine reuptake inhibitor RG1678: a pharmacological characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62:1152–1161.
   PubMed Web of Science ®Google Scholar
• Martin-Facklam M , Pizzagalli F , Zhou Y , et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology. 2013;38:504–512.
   PubMed Web of Science ®Google Scholar
• Umbricht D , Alberti D , Martin-Facklam M , et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia. A randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71:637–646.
   PubMed Web of Science ®Google Scholar
• Hofmann C , Pizzagalli F , Boetsch C , et al. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proof of mechanism studies in healthy volunteers. Psychopharmacology. 2016;233:2429–2439.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirol D , Blaettler T , Arango C , et al. Bitopertin in negative symptoms of schizophrenia-results from the Phase III Flashlyte and Daylyte studies. Biol Psychiatry. 2017;82:8–16.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim GMBH KG . Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament. WO 2013/017657 A1. 2013 Feb 7.
   Google Scholar
• Dart Neuroscience LLC . 2,4,5,6-Tetrahydroyrrolo[3,4-C]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-C]pyridine compounds as GlyT-1 inhibitors. WO 2015/164520. 2015.
   Google Scholar
• Dart Neuroscience LLC . Substituted azetidinyl compounds as GlyT-1 inhibitors. WO 2016/073420. 2016.
   Google Scholar
• Shanghai Institute of Materia Medica and Soochow University . GlyT-1 inhibitors. CN105712945. 2016.
   Google Scholar
• Shanghai Institute of Materia Medica and Soochow University . GlyT-1 inhibitors. CN105712928. 2016.
   Google Scholar
• Shanghai Institute of Materia Medica and Soochow University . GlyT-1 inhibitors. CN105712952. 2016.
   Google Scholar
• Jolidon S , Alberti D , Dowle A , et al. Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1. Bioorg Med Chem Lett. 2008;18:5533–5536.
   PubMedGoogle Scholar
• Glaxo Smith Kline . GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders. US 2011/0009440. 2011.
   Google Scholar
• Taisho Pharmaceutical Co . Substance capable of inhibiting glycine transporter. WO 2012/081665. 2012.
   Google Scholar
• Taisho Pharmaceutical Co . Glycine transporter inhibitor. WO 2013/187503. 2013.
   Google Scholar
• Glaxo Smith Kline Benzoxazine derivatives as glycine transport inhibitors. WO 2011/023753. 2011.
   Google Scholar
• Taisho Pharmaceutical Co . Glycine transporter-1 inhibitors. WO 2015/021400. 2015.
   Google Scholar
• Huang -C-C , Wei I-H , Huang C-L , et al. Inhibition of glycine transporter-1 as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74:734–741.
   PubMed Web of Science ®Google Scholar
• Barthel F , Urban A , Schlösser L , et al. Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats. Anesthesiology. 2014;121:160–169.
   PubMed Web of Science ®Google Scholar
• Morita K , Motoyama N , Kitayama T , et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models of mice. J Pharmacol Exp Ther. 2008;326:633–645.
   PubMed Web of Science ®Google Scholar
• Heinrich-Heine-Universität Düsseldorf . Glycine transporter-1 antagonists for the treatment of chronic and/or neuropathic pain. EP 3199156. 2017.
   Google Scholar
• Hirayasu Y , Sato S-I , Takahashi H , et al. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. BMC Psychiatry. 2016;16:1–11.
   PubMed Web of Science ®Google Scholar
• F Hoffman Laroche AG . GlyT-1 inhibitors for use in the treatment of hematological disorders. WO 2015/165842 A1. 2015 Nov 5.
   Google Scholar